Compare UTL & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UTL | ABUS |
|---|---|---|
| Founded | 1984 | 2005 |
| Country | United States | United States |
| Employees | N/A | 19 |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 906.9M | 848.8M |
| IPO Year | 1995 | 2008 |
| Metric | UTL | ABUS |
|---|---|---|
| Price | $51.11 | $4.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $56.50 | $5.00 |
| AVG Volume (30 Days) | 83.8K | ★ 1.6M |
| Earning Date | 05-04-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | 1.37 | ★ 55.26 |
| EPS | ★ 1.85 | 0.87 |
| Revenue | ★ $536,000,000.00 | $14,083,000.00 |
| Revenue This Year | $5.43 | N/A |
| Revenue Next Year | $4.22 | $239.71 |
| P/E Ratio | $27.60 | ★ $4.80 |
| Revenue Growth | 8.33 | ★ 128.21 |
| 52 Week Low | $45.11 | $3.04 |
| 52 Week High | $55.12 | $5.10 |
| Indicator | UTL | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 47.33 | 55.32 |
| Support Level | $51.05 | $4.17 |
| Resistance Level | $53.65 | $4.60 |
| Average True Range (ATR) | 1.19 | 0.16 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 50.12 | 81.25 |
Unitil Corp through its subsidiaries engages in the distribution of electricity and natural gas in its service territories in the states of New Hampshire, Massachusetts and Maine. Its natural gas operations include gas distribution utility operations and interstate gas transmission pipeline operations. It also engages in interstate natural gas transmission pipeline company, operating approximately 85 miles of underground gas transmission pipeline located in Maine and New Hampshire. The company's segments include Electric and Gas.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.